Population Pharmacokinetics and Exposure–Response with Teclistamab in Patients With Relapsed/Refractory Multiple Myeloma: Results From MajesTEC-1.

MLA

Miao, Xin, et al. “Population Pharmacokinetics and Exposure–Response with Teclistamab in Patients With Relapsed/Refractory Multiple Myeloma: Results From MajesTEC-1.” Targeted Oncology, vol. 18, no. 5, Sept. 2023, pp. 667–84. EBSCOhost, https://doi.org/10.1007/s11523-023-00989-z.

APA

Miao, X., Wu, L. S., Lin, S. X. W., Xu, Y., Chen, Y., Iwaki, Y., Kobos, R., Stephenson, T., Kemmerer, K., Uhlar, C. M., Banerjee, A., Goldberg, J. D., Trancucci, D., Apte, A., Verona, R., Pei, L., Desai, R., Hickey, K., Su, Y., & Ouellet, D. (2023). Population Pharmacokinetics and Exposure–Response with Teclistamab in Patients With Relapsed/Refractory Multiple Myeloma: Results From MajesTEC-1. Targeted Oncology, 18(5), 667–684. https://doi.org/10.1007/s11523-023-00989-z

Chicago

Miao, Xin, Liviawati S. Wu, Shun Xin Wang Lin, Yan Xu, Yang Chen, Yuki Iwaki, Rachel Kobos, et al. 2023. “Population Pharmacokinetics and Exposure–Response with Teclistamab in Patients With Relapsed/Refractory Multiple Myeloma: Results From MajesTEC-1.” Targeted Oncology 18 (5): 667–84. doi:10.1007/s11523-023-00989-z.